Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
-
Trump hails Paxton win in Texas Senate runoff
-
Duterte's ICC trial to start November 30: judge
-
Arteta adamant English title can inspire Arsenal to Champions League glory
-
Yapp named coach of British and Irish Lions women's team
-
Swiatek sees off Bejlek to reach third round at French Open
-
Health workers battle with few resources on DR Congo's Ebola front line
-
Giant Messi statue in India to be removed over safety concerns
-
Bolivia blockades make saving lives 'ordeal'
-
Kanye West to play Istanbul show on May 30
-
Nuno to stay on as West Ham boss after relegation
-
German far-left militant jailed for 13 years for robberies
-
Iran says 'low' possibility of return to war with US
-
Germany warns on trade imbalance as economy minister visits China
-
Asia stocks see tech gains as investors weigh US-Iran deal
-
Argentina coach Scaloni encouraged by news on Messi injury
-
Hajj pilgrims stone the devil in final ritual
-
Frugal and more online: smarter spenders rewrite luxury's China dream
-
Tibet-in-exile government leader sworn in
-
Nvidia to boost spending in Taiwan to $150 bn a year
-
All Blacks captain Barrett out of South Africa tour, faces back surgery
-
Value of South Korean chip giant SK hynix tops $1 tn
-
Gilgeous-Alexander, Thunder down Spurs to take 3-2 series lead
-
Love birds: twice-extinct parakeet gets lifeline from randy pair
-
Netherlands under the radar as they chase long-awaited World Cup crown
-
Sweden bidding to make most of back-door World Cup entry
-
Deforestation in Brazil's Amazon drops to lowest level since 2019
-
Asia stocks mixed over hopes of US-Iran deal, tech gains
-
Swiatek, Zverev, Djokovic in action as French Open hots up
-
Madrid pumps up the volume on Latin music
-
South Korea's Son 'feeling great' for World Cup despite goal drought
-
'My job is going': UK workers squeezed out by AI
-
Marsh out of Pakistan ODIs, Inglis to captain Australia
-
No feasts, no joy: Gazans mark a dark Eid
-
Low cost glasses help India's poor see a better future
-
From barefoot kid, to millionaire star, Caiceido keeps chasing trophies
-
Germany enter World Cup Group E with score to settle
-
Luis Enrique's PSG eye greatness with back-to-back Champions Leagues in sight
-
Buoyant Japan coach targets World Cup glory despite Mitoma blow
-
Bolivian Congress OK's use of troops against protesters
-
'I'm still lost': Los Angeles airport baffles travellers ahead of World Cup
-
Canadian who supplied poison for suicides to plead guilty
-
Boston Celtics' Mazzulla named NBA coach of the year
-
Thousands rally for EU on Georgia independence day
-
Trump builds giant stage at White House for birthday cage fight
-
AmeriTrust Announces First Quarter 2026 Financial Results
-
Ecrypt Inc. Named Finalist in the 2026 U.S. Customer Experience Awards
-
Arrive AI unveils Arrive OS, further delivering on Autonomy Unlocked Strategy
-
Avid Expands Executive Team: Names Parrish Snyder as Chief Revenue Officer, Erik Tomalis as Chief Community Officer
-
Victory Marine Holdings Announces Completion of Initial GUTSI(TM) Production and U.S. Market Launch
-
Mocse Credit Union Selects Narmi to Replace Legacy Platform with Full-Stack Digital Banking Solution
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL.
The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activity and improve antitumor responses.
Presentation Details:
Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session)
Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy
Poster Board: 410
Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT
Presenter: Alexey V. Stepanov, PhD
The poster will be available to conference attendees during the scheduled session. For more information, please visit asco.org.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
G.Stevens--AMWN
